Roche Could Have The Best Obesity Pill

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

That is, if very early data in a handful of patients are borne out in later, larger studies.    

Pills and dollars

The data are early both in terms of trial stage and time point, but Roche Holding AG’s newly acquired CT-996 looks like it might be the most effective obesity pill yet. The GLP-1 agonist, which Roche got when it bought Carmot Therapeutics Inc. for $2.7bn in December, looks more effective even than Viking Therapeutics, Inc.’s VK2735 – though this asset is more advanced.

Key Takeaways

  • Roche’s oral GLP-1 agonist CT-996 posted highly positive four-week weight loss data in 25 obesity patients.

The new efficacy data come from 25 patients in an ongoing Phase I trial of CT-996, and concern a cut...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains